| |
|
 AGI’s taxane sensitivity marker, Mammotax, recently published in Breast Cancer Research. Mammotax is a single antibody immunohistochemistry test for assessing whether a patient will respond to taxane therapy. A discovery and validation study were published in the March 23 issue of Breast Cancer Research. AGI is currently evaluating Mammotax in several additional independent clinical cohorts.
|
|
|
|
Mammostrat is now available through Pathology Associates. A novel molecular-targeted immunohistochemistry test for the risk profiling of ER+ breast cancer patients is available for testing from Pathology Associates in Huntsville, AL. To find out more about Mammostrat and how to order this product, click here.
|
|
